AHMAD AWADA ET AL: "Phase I trial to investigate the safety, pharmacokinetics and efficacy of sorafenib combined with docetaxel in patients with advanced refractory solid tumours", EUROPEAN JOURNAL OF CANCER, vol. 48, no. 4, 27 January 2012 (2012-01-27), pages 465-474, XP028456373, ISSN: 0959-8049, DOI: 10.1016/J.EJCA.2011.12.026 [retrieved on 2012-01-03] (B1)

ASTRID PEDERSEN ET AL: "Sorafenib and nilotinib resensitize tamoxifen resistant breast cancer cells to tamoxifen treatment via estrogen receptor [alpha]", INTERNATIONAL JOURNAL OF ONCOLOGY, vol. 45, 22 August 2014 (2014-08-22), pages 2167-2175, XP055336103, GR ISSN: 1019-6439, DOI: 10.3892/ijo.2014.2619 (B1)

E SAMALIN ET AL: "Sorafenib and irinotecan (NEXIRI) as second- or later-line treatment for patients with metastatic colorectal cancer and KRAS-mutated tumours: a multicentre Phase I/II trial", BRITISH JOURNAL OF CANCER, vol. 110, no. 5, 9 January 2014 (2014-01-09), pages 1148-1154, XP055396725, GB ISSN: 0007-0920, DOI: 10.1038/bjc.2013.813 (B1)

EP-A2- 1 526 851 (B1)

ESTELLE DAUDIGEOS-DUBUS ET AL: "Regorafenib: Antitumor Activity upon Mono and Combination Therapy in Preclinical Pediatric Malignancy Models", PLOS ONE, vol. 10, no. 11, 23 November 2015 (2015-11-23), page e0142612, XP055396189, DOI: 10.1371/journal.pone.0142612 (B1)

JAN STENVANG ET AL: "DEN-50R - establisment of a novel and unique cell line based drug screening platform for cancer treatment", AACR-NCI-EORTC SYMPOSIUM: MOLECULAR TARGETS AND CANCER THERAPEUTICS, 2015, 24 September 2015 (2015-09-24), XP055396150, Hynes Convention Center Boston, Massachusetts, USA (B1)

WO-A1-2007/104719 (B1)

JAW-YUAN WANG ET AL: "FOLFIRI and regorafenib combination therapy with dose escalation of irinotecan as fourth-line treatment for patients with metastatic colon cancer according to UGT1A1 genotyping", ONCOTARGETS AND THERAPY, 1 November 2014 (2014-11-01), page 2143, XP055396718, DOI: 10.2147/OTT.S69774 (B1)

KRISTINE H LETHERT ET AL: "Fulvestrant (F) plus sorafenib (S) as salvage therapy for hormone receptor positive (HR+) metastatic breast cancer (MBC) failing prior aromatase inhibitor (AI) treatment.:", JOURNAL OF CLINICAL ONCOLOGY:, vol. 30, no. 15 suppl, 1 May 2012 (2012-05-01), page e11042, XP055396738, (B1)

MROSS ET AL: "Results from an in vitro and a clinical/pharmacological phase I study with the combination irinotecan and sorafenib", EUROPEAN JOURNAL OF CA, ELSEVIER, AMSTERDAM, NL, vol. 43, no. 1, 10 January 2007 (2007-01-10), pages 55-63, XP005834905, ISSN: 0959-8049, DOI: 10.1016/J.EJCA.2006.08.032 (B1)

ROBERTA SCHMIEDER ET AL: "Regorafenib (BAY 73-4506): Antitumor and antimetastatic activities in preclinical models of colorectal cancer : Antitumor and antimetastatic activities of regorafenib", INTERNATIONAL JOURNAL OF CANCER, vol. 135, no. 6, 15 September 2014 (2014-09-15), pages 1487-1496, XP055396721, US ISSN: 0020-7136, DOI: 10.1002/ijc.28669 (B1)

WEIJING SUN ET AL: "Phase II Study of Sorafenib in Combination With Docetaxel and Cisplatin in the Treatment of Metastatic or Advanced Gastric and Gastroesophageal Junction Adenocarcinoma: ECOG 5203", JOURNAL OF CLINICAL ONCOLOGY, vol. 28, no. 18, 20 June 2010 (2010-06-20) , pages 2947-2951, XP055396732, US ISSN: 0732-183X, DOI: 10.1200/JCO.2009.27.7988 (B1)

JAN STENVANG, THIAGO LIMA, SIGNE LYKKE NIELSEN, JORGEN DREJER, NILS BRUNNER, PALLE CHRISTOPHERSEN: "The volume regulated anion channel inhibitor NS3728 to enhance the cytotoxic effects of SN-38 in human colorectal cancer cells grown in vitro.", JOURNAL OF CLINICAL ONCOLOGY, vol. 34, no. 15 suppl, E23170, 20 May 2016 (2016-05-20), XP9195160, (B1)